OptimizeRx (OPRX) to Release Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRXGet Rating) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, May 10th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $14.48 on Monday. The business’s fifty day moving average price is $14.75 and its 200 day moving average price is $16.82. OptimizeRx has a 12 month low of $12.20 and a 12 month high of $30.82.

Wall Street Analysts Forecast Growth

OPRX has been the topic of several research reports. Royal Bank of Canada dropped their price objective on OptimizeRx from $22.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, March 9th. Roth Capital reaffirmed a “buy” rating on shares of OptimizeRx in a report on Thursday, March 9th. Lake Street Capital dropped their price objective on OptimizeRx from $25.00 to $18.00 in a report on Thursday, March 9th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a report on Tuesday, March 21st. Finally, SVB Leerink reissued an “outperform” rating on shares of OptimizeRx in a report on Friday, January 27th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. lifted its position in OptimizeRx by 18.3% in the fourth quarter. Alliancebernstein L.P. now owns 25,731 shares of the company’s stock valued at $432,000 after purchasing an additional 3,987 shares during the period. Connors Investor Services Inc. lifted its position in OptimizeRx by 13.6% in the fourth quarter. Connors Investor Services Inc. now owns 12,500 shares of the company’s stock valued at $210,000 after purchasing an additional 1,500 shares during the period. State of Wisconsin Investment Board lifted its position in OptimizeRx by 51.1% in the fourth quarter. State of Wisconsin Investment Board now owns 40,723 shares of the company’s stock valued at $684,000 after purchasing an additional 13,776 shares during the period. Norges Bank acquired a new stake in OptimizeRx in the fourth quarter valued at about $906,000. Finally, Marshall Wace LLP lifted its position in OptimizeRx by 8.0% in the fourth quarter. Marshall Wace LLP now owns 63,888 shares of the company’s stock valued at $1,073,000 after purchasing an additional 4,741 shares during the period. Institutional investors and hedge funds own 80.45% of the company’s stock.

About OptimizeRx

(Get Rating)

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support.

Featured Stories

Earnings History for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.